XML 58 R42.htm IDEA: XBRL DOCUMENT v3.10.0.1
INTANGIBLE ASSETS, NET (Details Narrative)
3 Months Ended 12 Months Ended
Aug. 06, 2018
USD ($)
$ / shares
shares
Sep. 30, 2018
USD ($)
Dec. 31, 2018
USD ($)
Number
Dec. 31, 2017
USD ($)
Dec. 31, 2016
USD ($)
Finite-Lived Intangible Assets [Line Items]          
Amortization expense | $     $ 112,474 $ 71,516 $ 54,545
Subscription Agreement [Member] | Knight Therapeutics Inc. [Member]          
Finite-Lived Intangible Assets [Line Items]          
Issue of common stock shares (in shares) | shares 3,921,568        
Common stock sale price (in dollars per share) | $ / shares $ 5.10        
Gross proceeds | $ $ 20,000,000        
Approved Hormone Therapy Drug Candidate Patents [Member]          
Finite-Lived Intangible Assets [Line Items]          
Useful Life     20 years    
Domestic U.S. Patents [Member]          
Finite-Lived Intangible Assets [Line Items]          
Number of issued patents     21    
Foreign Patents [Member]          
Finite-Lived Intangible Assets [Line Items]          
Number of issued patents     24    
Domestic Utility Patents [Member]          
Finite-Lived Intangible Assets [Line Items]          
Number of issued patents     11    
Foreign Utility Patents [Member]          
Finite-Lived Intangible Assets [Line Items]          
Number of issued patents     5    
Domestic Patents - TX-004HR [Member]          
Finite-Lived Intangible Assets [Line Items]          
Number of issued patents     3    
Foreign Patents - TX-004HR [Member]          
Finite-Lived Intangible Assets [Line Items]          
Number of issued patents     12    
Domestic Utility Patent - Transdermal Patch Candidates [Member]          
Finite-Lived Intangible Assets [Line Items]          
Number of issued patents     1    
Foreign Utility Patent - Transdermal Patch Candidates [Member]          
Finite-Lived Intangible Assets [Line Items]          
Number of issued patents     4    
Domestic Utilty Patent - Opera Software [Member]          
Finite-Lived Intangible Assets [Line Items]          
Number of issued patents     1    
Domestic Patents - TX-009HR [Member]          
Finite-Lived Intangible Assets [Line Items]          
Number of issued patents     1    
Foreign Patents Progesterone - Only Candidate [Member]          
Finite-Lived Intangible Assets [Line Items]          
Number of issued patents     3    
Domestic Utility Patents Topical - Cream Candidates [Member]          
Finite-Lived Intangible Assets [Line Items]          
Number of issued patents     1    
Council License Agreement [Member]          
Finite-Lived Intangible Assets [Line Items]          
Payment of milestone recorded as finite-lived intangible asset | $   $ 20,000,000      
Council License Agreement [Member] | ANNOVERA [Member]          
Finite-Lived Intangible Assets [Line Items]          
Milestone payments upon FDA approval | $     $ 20,000,000    
Milestone payments (payment after release of first commercial batch) | $     $ 20,000,000    
Annual royalty rate reduction of initial rate during the six-month period from commercial sale of a generic equivalent     50.00%    
Annual royalty rate reduction of initial rate after the six-month period from commercial sale of a generic equivalent     20.00%    
Maximum costs and expenses for post approval study to be paid by the Company | $     $ 20,000,000    
Council License Agreement [Member] | ANNOVERA [Member] | Step-based Royalty Payment One [Member]          
Finite-Lived Intangible Assets [Line Items]          
Royalty (percent)     5.00%    
Council License Agreement [Member] | ANNOVERA [Member] | Step-based Royalty Payment One [Member] | Maximum [Member]          
Finite-Lived Intangible Assets [Line Items]          
Net sales amount per step-based royalty | $     $ 50,000,000    
Council License Agreement [Member] | ANNOVERA [Member] | Step-based Royalty Payment Three [Member]          
Finite-Lived Intangible Assets [Line Items]          
Royalty (percent)     15.00%    
Council License Agreement [Member] | ANNOVERA [Member] | Step-based Royalty Payment Three [Member] | Minimum [Member]          
Finite-Lived Intangible Assets [Line Items]          
Net sales amount per step-based royalty | $     $ 150,000,000    
Council License Agreement [Member] | ANNOVERA [Member] | Step-based Royalty Payment Two [Member]          
Finite-Lived Intangible Assets [Line Items]          
Royalty (percent)     10.00%    
Council License Agreement [Member] | ANNOVERA [Member] | Step-based Royalty Payment Two [Member] | Minimum [Member]          
Finite-Lived Intangible Assets [Line Items]          
Net sales amount per step-based royalty | $     $ 50,000,000    
Council License Agreement [Member] | ANNOVERA [Member] | Step-based Royalty Payment Two [Member] | Maximum [Member]          
Finite-Lived Intangible Assets [Line Items]          
Net sales amount per step-based royalty | $     $ 150,000,000